https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 3048)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 3048)2015-05-30 00:00:002015-05-30 00:00:00Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)2015-05-29 00:00:002015-05-29 00:00:00A study of mature alpha-DC-1 vaccine to induce immune responses in ovarian cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-29 / J. Immunol. 2015 Jul;195(1):367-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-29 / J. Immunol. 2015 Jul;195(1):367-762015-05-29 00:00:002019-02-15 08:47:19Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-28 / Immunotherapy 2015;7(8):855-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-21 / World J. Gastroenterol. 2015 May;21(19):5778-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-21 / World J. Gastroenterol. 2015 May;21(19):5778-932015-05-21 00:00:002015-05-21 00:00:00Gastric cancer and the epoch of immunotherapy approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-20 / Front Immunol 2015;6:243
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-20 / Front Immunol 2015;6:2432015-05-20 00:00:002019-02-15 08:45:05Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-18 / BJU Int. 2015 Sep;116(3):321-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-18 / BJU Int. 2015 Sep;116(3):321-92015-05-18 00:00:002019-02-15 08:45:12Advances in the understanding of cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-01 / J. Immunother. 2015 May;38(4):155-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-01 / J. Immunother. 2015 May;38(4):155-642015-05-01 00:00:002019-02-15 08:45:07Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-17 / Eur. J. Immunol. 2015 Jun;45(6):1783-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-17 / Eur. J. Immunol. 2015 Jun;45(6):1783-932015-04-17 00:00:002019-02-15 08:45:04Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-14 / Chonnam Med J 2015 Apr;51(1):1-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-14 / Chonnam Med J 2015 Apr;51(1):1-72015-04-14 00:00:002019-02-15 08:51:23Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
